Rise in Imported Chikungunya Cases Linked to Cuba Outbreak
The Robert Koch Institute (RKI) has reported a notable increase in imported Chikungunya fever cases among travelers returning to Germany, with a significant proportion connected to recent visits to Cuba. According to the latest RKI epidemiological bulletin, 171 cases of Chikungunya infection were identified among travelers during the current reporting period, with 33 of these cases traced back to trips to Cuba, particularly throughout November and December.
Historically, Cuba had reported few or no cases of Chikungunya among travelers in previous years. However, the latest outbreak on the island has raised concerns, with experts attributing the increased transmission to the aftermath of Hurricane Melissa, which struck at the end of October. The hurricane's impact likely created favorable conditions for the proliferation of mosquito populations, which are the primary vectors for Chikungunya virus transmission.
Despite intensified efforts to control mosquito populations in affected regions, the risk of infection for travelers remains elevated. The RKI has issued an advisory for individuals planning to visit Cuba and other affected areas, emphasizing the importance of stringent mosquito protection measures. Travelers are encouraged to use insect repellents, wear long-sleeved clothing, and take additional precautions to minimize exposure to mosquito bites.
Chikungunya is a viral disease transmitted by Aedes mosquitoes, characterized by symptoms such as high fever, severe joint pain, and skin rashes. The illness can have a significant impact on quality of life, especially for those experiencing persistent joint pain after the acute phase. The RKI recommends that healthcare professionals consider Chikungunya fever in the differential diagnosis of returning travelers who present with fever, joint pain, or rashes, particularly if they have recently visited outbreak regions like Cuba.
In response to the elevated risk, two vaccines against Chikungunya are currently approved within the European Union: Ixchiq® (Valneva) and Vimkunya® (Bavarian Nordic). Since July 2025, the Standing Committee on Vaccination (STIKO) has recommended vaccination for individuals aged twelve years and older who are planning to travel to regions experiencing ongoing Chikungunya outbreaks. However, there have been supply shortages of the Vimkunya® vaccine, with limited availability expected to persist through the end of the year. To address this issue, the Paul Ehrlich Institute has authorized the importation of Vimkunya® vials with French labeling to alleviate the shortage.
Travelers to affected regions are strongly advised to consult healthcare professionals before departure to assess their risk and discuss vaccination options. In addition to vaccines, implementing comprehensive mosquito protection strategies remains essential for reducing the likelihood of infection. These strategies include staying in accommodations with screened windows or air conditioning and avoiding areas with high mosquito activity, especially during peak biting hours.
The rise in imported Chikungunya cases underscores the importance of vigilance among travelers and healthcare providers. As global travel resumes and climate events increase the risk of vector-borne diseases, coordinated public health measures and informed travel practices play a critical role in mitigating the spread of infectious diseases such as Chikungunya.